ArticleSignal transduction and targeted therapy2026
Rationale for multi-epitope TGFβ vaccination in pancreatic cancer: evidence from immunologic and clinical correlates.
Article in Signal transduction and targeted therapy, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Immune regulation includes an effector arm: therapeutic implications of phase III IDO/PD-L1 vaccination in melanoma.Signal transduction and targeted therapy · 2026Article
- Immune modulatory vaccines targeting tumor microenvironment antigens: recent advances in oncology and beyond.Signal transduction and targeted therapy · 2026Review
- IL-6 as a central driver of immune evasion in PDAC: from IDO-mediated tolerance to multi-pathway immunosuppression.Frontiers in immunology · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Transforming growth factor beta (TGFβ) plays a crucial role in pancreatic ductal adenocarcinoma (PDAC) progression by promoting immune suppression, fibrosis, and metastasis. Given its central role in shaping the tumor microenvironment, TGFβ has attracted significant clinical interest as a target for immunotherapy. One promising and innovative approach involves TGFβ-based immune-modulatory vaccines (IMVs). In this study, we explored the immunogenic potential of multiple TGFβ-derived epitopes and assessed the clinical relevance of TGFβ-specific T cells in PDAC patients. We identified T cell responses towards multiple epitopes, TGFβ‑15, TGFβ‑33, and TGFβ‑38, in both healthy donors and PDAC patients, with TGFβ‑33 eliciting particularly robust responses in the patient cohort. These primarily CD4⁺ T cells displayed proinflammatory, as well as notable cytotoxic, properties and recognized target cells in a TGFβ-dependent manner. Moreover, we found that higher baseline frequencies of TGFβ‑33-specific T cells correlated with improved clinical outcomes following combined immune checkpoint inhibitor therapy and radiotherapy. Interestingly, patients with baseline responses to multiple TGFβ-derived epitopes had longer overall and progression-free survival compared to those with responses to none or a single epitope. Using a single mRNA construct encoding multiple TGFβ epitopes, we demonstrated effective activation of T cells specific for distinct TGFβ epitopes. These findings support the potential of a multi-epitope TGFβ-derived immune-modulatory vaccine to enhance anti-tumor immunity, representing a promising strategy to improve therapeutic responses in PDAC.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.